What is Jazz Pharmaceuticals's revenue?

Jazz Pharmaceuticals (JAZZ) generated $4.4B in revenue over the trailing twelve months, up 9.2% year over year.

Is Jazz Pharmaceuticals profitable?

Jazz Pharmaceuticals is not currently profitable: it reported a net loss of $266.5M over the trailing twelve months, a -8.9% net margin.

What is Jazz Pharmaceuticals's earnings per share?

Jazz Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.75.

Where does Jazz Pharmaceuticals's income statement data come from?

Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Jazz Pharmaceuticals JAZZ Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$4.27B+4.9%	$4.07B+6.1%	$3.83B+4.8%	$3.66B+18.3%
Research and development	——	——	——	——
Selling, general and administrative	$1.81B+30.6%	$1.39B+3.1%	$1.34B-5.2%	$1.42B-2.4%
Compensation and benefits	$291.13M+17.4%	$248.05M—	——	——
Advertising	$105.6M-1.7%	$107.4M+16.5%	$92.2M-15.3%	$108.8M-32.6%
Depreciation and amortization	——	——	——	——
Other operating expenses	——	——	——	——
Total costs & expenses	$4.7B+40.1%	$3.35B+3.0%	$3.26B-12.6%	$3.72B+27.4%
Operating income	——	$716.63M+23.9%	$578.58M+983%	-$65.53M-138%
Interest expense	$248.56M-21.0%	$314.82M-5.5%	$333.11M+23.1%	$270.67M+95.8%
Interest income	$85.8M-19.4%	$106.4M+63.4%	$65.1M+466%	$11.5M+539%
Other income (expense), net	——	-$17.98M+42.6%	-$31.31M—	——
Income from equity method investments	-$690K+58.4%	-$1.66M+44.8%	-$3.01M+69.7%	-$9.92M-1,289%
Income before income taxes	——	$470.35M+57.9%	$297.93M+180%	-$372.78M-230%
Income tax expense	-$277.39M-203%	-$91.43M+23.8%	-$119.91M+24.4%	-$158.65M-169%
Net income	——	$560.12M+35.0%	$414.83M+285%	-$224.06M+32.0%
Diluted earnings per share	——	$8.70+41.9%	$6.13+272%	-$3.57+34.1%
Basic earnings per share	——	$9.08+38.6%	$6.55+283%	-$3.57+33.3%
Weighted-average shares, diluted	244.8M-6.3%	261.3M-10.1%	290.7M+15.5%	251.7M+5.4%
Weighted-average shares, basic	243.9M-1.9%	248.7M-2.1%	253.9M+1.7%	249.6M+5.4%
Interest Income (Expense), Nonoperating	-$195.05M+18.1%	-$238.1M+17.7%	-$289.44M-0.4%	-$288.24M-3.4%
Additional expected tax expense if foreign earnings repatriated	$56M-30.9%	$81M+1.5%	$79.8M-40.9%	$135M+19.5%
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	$75.22M+30.2%	$57.75M+13.3%	$50.95M+12.1%	$45.44M+27.6%
Share-based compensation expense related to employee stock plans	$294.29M+17.4%	$250.69M+10.3%	$227.32M+1.8%	$223.28M+17.9%
Advertising costs	$105.6M-1.7%	$107.4M+16.5%	$92.2M-15.3%	$108.8M-32.6%
Pre-tax stock-based compensation cost	$291.18M+17.4%	$248.05M+9.3%	$226.84M+2.2%	$222M+17.5%
Share-Based Payment Arrangement, Expense, after Tax	$239.3M+15.3%	$207.49M+11.1%	$186.83M+3.3%	$180.94M+16.6%
Amortization of capitalized software and acquired intangible assets	$654.61M+4.4%	$627.31M+3.1%	$608.28M+1.5%	$599.17M+14.0%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	$906.55M—	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$22.91M—	——	$698.19M—	——
Cost of product sales (excluding amortization of acquired developed technologies)	$503.28M+12.9%	$445.71M+2.3%	$435.58M-19.4%	$540.52M+22.6%
Federal	$71.63M-26.7%	$97.68M+26.3%	$77.34M+25.7%	$61.55M+139%
De-recognition of finance lease asset on lease assignment / termination	$903K—	$0—	$0—	——
De-recognition of finance lease liability on lease assignment / termination	$1.02M—	$0—	$0—	——
De-recognition of operating lease asset on lease assignment / termination	$2.34M-88.2%	$19.88M+377%	$4.17M—	$0-100%
De-recognition of operating lease liability on lease assignment / termination	$2.3M-89.2%	$21.3M+378%	$4.46M—	$0-100%
Maximum allowable dividend and restricted payments	$350M0.0%	$350M+1,067%	$30M0.0%	$30M0.0%
Maximum allowable dividend and restricted percentage	——	——	——	——
Maximum secured leverage ratio, for restricted payments to be allowed	——	——	——	——
Minimum secured leverage ratio, for restricted payments to be allowed	——	——	——	——
Federal	-$9.82M+51.0%	-$20.02M-83.4%	-$10.92M+82.4%	-$62.01M-1,051%
Deferred taxes	-$444.97M-114%	-$208.33M+19.9%	-$260.22M+11.0%	-$292.25M—
Deferred Income Tax Expense (Benefit), Before Effect Of Change In Tax Rates	-$442.9M-112%	-$209.27M+19.4%	-$259.66M+5.7%	-$275.46M-43.4%
Deferred Income Tax Expense (Benefit), Increase (Decrease) In Tax Rate	-$2.08M-321%	$938K+269%	-$556K+96.7%	-$16.79M-106%
Other	$0+100%	-$17K—	$0+100%	-$2K-140%
Deferred Other Tax Expense Benefit	-$13.58M-18.3%	-$11.48M-27.7%	-$8.99M+19.3%	-$11.14M+61.0%
Depreciation	$41.64M+27.1%	$32.75M+7.7%	$30.41M+0.4%	$30.3M+13.4%
Dividends, Common Stock, Cash	$0—	$0—	$0—	$0—
Effect of exchange rate changes on cash, cash equivalents and restricted cash	$6.56M+491%	-$1.68M—	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Change in estimate, amount	——	-$106.01M-1,837%	-$5.47M+61.1%	-$14.07M-430%
Effect of cross-border tax laws	$29.81M—	——	——	——
Effect of cross-border tax laws	——	——	——	——
Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary	——	——	——	——
Effective Income Tax Rate Reconciliation, FDII, Amount	$28.62M-27.5%	$39.47M-6.9%	$42.4M+43.5%	$29.54M+765%
Effective Income Tax Rate Reconciliation, FDII, Percent	——	——	——	——
Non-deductible contingent consideration payments	$7.64M—	——	——	——
Non-deductible contingent consideration payments	——	——	——	——
Non-deductible AIPR&D	——	——	——	——
Other	-$0—	——	——	——
Non-deductible facility expense	——	$22K-99.9%	$16.62M+105%	$8.09M—
Share-based compensation	——	——	——	——
Non-deductible financing costs	——	$22.44M+42.9%	$15.71M+249%	$4.5M-68.8%
Patent box incentive benefit, amount	$60.99M-6.8%	$65.41M+372%	$13.86M+123%	$6.2M—
Effective Income Tax Rate Reconciliation, Patent Box Incentive Benefit, Percent	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——
Excess tax benefits associated with employee equity plans	$5.05M-72.1%	$18.07M+357%	$3.96M+334%	-$1.69M+69.6%
State income taxes – net of federal income tax benefit	——	——	——	——
Changes in unrecognized tax benefits	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——
Share-Based Payment Arrangement, Expense, Tax Benefit	$51.88M+27.9%	$40.55M+1.3%	$40.02M-2.5%	$41.06M+21.5%
Income tax benefit realized from option exercises	$5M+1,567%	$300K-84.2%	$1.9M-76.3%	$8M-14.0%
Gain (Loss), Foreign Currency Transaction, before Tax	-$2.56M+68.8%	-$8.18M-193%	$8.79M+146%	-$19.01M-337%
Gain Loss On Sale Of Other Assets	——	——	——	——
Foreign Currency Translation and Other Adjustments	——	——	——	——
Income Loss From Continuing Operations Before Income Taxes Domestic	$164.7M-66.9%	$497.86M+10.8%	$449.21M+993%	-$50.31M-152%
Federal taxes	$82.36M—	——	——	——
Foreign	$39.45M—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	-$199.91M-199%	$202M+169%	$75.08M-21.0%	$95.05M+16.9%
Income Tax Reconciliation Change In Enacted Tax Rate	——	$938K+255%	-$605K+96.4%	-$16.79M-106%
Equity income or loss	$90.79M-49.7%	$180.46M+17.4%	$153.66M—	——
Income Tax Reconciliation Foreign Income Tax Rate Differential	——	$38.35M+594%	-$7.76M-232%	$5.86M+235%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	-$78.48M-233%	$58.79M+57.9%	$37.24M+180%	-$46.6M-230%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	$963K—	——	——	——
Non-deductible IPR&D charges	$187.35M—	——	——	——
Share-based compensation	$8.86M-18.7%	$10.89M-22.7%	$14.09M+4.3%	$13.51M-32.2%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$3.91M+6.9%	$3.66M-16.5%	$4.39M+128%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	-$5.48M—	——	——	——
Changes in unrecognized tax benefits	-$6.44M-166%	$9.77M+177%	-$12.61M—	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$35.33M-45.9%	$65.26M+30.8%	$49.9M+78.4%	$27.98M-10.0%
Income Taxes Paid, Net	$121.81M+6.0%	$114.91M-35.4%	$177.88M—	——
Accounts payable	——	——	——	——
Increase (Decrease) in Accounts Receivable	$106.28M+384%	$21.98M-57.6%	$51.88M-42.4%	$90.14M-9.5%
Increase Decrease In Accrued Income Taxes Payable	——	-$14.74M—	——	——
Accrued liabilities	$77.1M—	——	——	$165.99M+16.6%
Increase (Decrease) in Inventories	$93.76M+106%	$45.54M+239%	$13.42M-73.4%	$50.46M+3.3%
Other liabilities	——	-$39.27M-66.4%	-$23.6M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$127.12M+450%	-$36.3M-144%
Incremental Common Shares Attributable To Conversion Of Debt Securities	0-100%	11.3M—	——	——
Add - Incremental shares under stock-based compensation plans (in shares)	$910K+4.1%	$874K—	——	$0-100%
Interest Paid, Excluding Capitalized Interest, Operating Activity	$248.55M-21.0%	$314.82M-5.5%	$333.11M+23.1%	$270.67M+95.8%
Acquisition accounting inventory fair value step-up adjustment	$147.95M+9.6%	$135.01M—	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$948.82M—	——	-$305.25M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$1.51B—	——	——	-$450.83M+91.4%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$1.36B-2.9%	$1.4B+27.8%	$1.09B-14.1%	$1.27B+63.4%
Non-cash interest expense	$32.54M+48.1%	$21.97M—	——	——
Number of operating segments	——	——	10.0%	1—
Number of reportable segments	1—	——	——	——
Other comprehensive income/(loss) before reclassifications	——	——	——	——
Foreign currency translation	$380.08M+458%	-$106.03M-137%	$283.13M—	——
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	$102K-94.2%	$1.76M—	——	$0-100%
Net gains (losses) deferred	$251K-95.3%	$5.3M—	——	$0—
Tax on unrealized gain on derivative hedge agreements	$379K-76.2%	$1.59M+40.1%	$1.14M—	$0—
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax	$1.32M-72.6%	$4.79M+40.0%	$3.42M—	$0—
Other comprehensive income/(loss)	$379.01M+459%	-$105.52M-137%	$283.36M—	——
Other Noncash Income (Expense)	——	-$19.62M—	——	$14.49M—
Payment, Tax Withholding, Share-Based Payment Arrangement	$75.22M+30.2%	$57.75M+13.3%	$50.95M+12.1%	$45.44M+27.6%
Payments to Acquire Intangible Assets	$108.5M—	$0—	$0-100%	$25M+39.7%
Payments to Acquire Investments	$1.83B+40.2%	$1.31B+235%	$390.1M+539%	$61.04M+128%
Payments to Acquire Other Productive Assets	——	——	——	——
Payments to Acquire Property, Plant, and Equipment	$58.75M+54.3%	$38.07M+58.9%	$23.96M—	——
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$107.86M+422%	$20.65M-55.6%	$46.46M-52.6%	$98.02M-27.5%
Proceeds from disposition of marketable securities and other investments	$1.36B+60.9%	$845M+213%	$270M+350%	$60M—
Proceeds from sale of assets	——	$0—	$0—	——
Provision for losses on accounts receivable and inventory	$19.11M-31.2%	$27.76M—	——	——
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$1.31M—	——	——	-$128K+95.3%
Repayments of Secured Debt	$781M+2,419%	$31M—	——	——
Research and development expense	$782.78M-11.4%	$884M+4.0%	$849.66M+43.9%	$590.45M+16.7%
Revenue From Contract With Customer Excluding Assessed Tax	$4.27B+4.9%	$4.07B+6.1%	$3.83B+4.8%	$3.66B+18.3%
Percentage of post-tax proceeds entitled	——	——	——	——
Stock-based compensation	$291.13M+17.4%	$248.05M+9.3%	$226.84M+2.2%	$222M+17.5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	——	——	——	——
Intrinsic value of stock options exercised	$21.7M+10,750%	$200K-96.8%	$6.3M-81.9%	$34.8M-32.8%
Options forfeited/expired (in dollars per share)	——	——	——	——
Exercised (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——
Stock Issued During Period, Value, Stock Options Exercised	$88.47M+5,331%	$1.63M-94.6%	$30.19M-63.6%	$82.9M-30.4%
Tangible Asset Impairment Charges	$0—	$0-100%	$61.01M—	$0—
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions	$648K+332%	$150K-98.8%	$12.7M+7,645%	$164K-9.9%
Unrecognized tax benefits, settlements	$0-100%	$2.61M—	$0-100%	$223K-98.5%
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions	$24.54M-24.6%	$32.56M+117%	$15M-40.3%	$25.13M-5.8%
Unrecognized Tax Benefits Increases Resulting From Acquisition	$18.66M—	$0—	$0—	$0-100%
Additions for tax positions of prior years	$1.2M—	$0-100%	$224K-92.0%	$2.79M+1,224%
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations	$26.71M+0.7%	$26.52M+11.4%	$23.81M+11.1%	$21.43M-19.3%
EBIT	——	$716.63M+23.9%	$578.58M+983%	-$65.53M-138%
EBITDA	——	$749.43M+23.1%	$608.98M+1,829%	-$35.23M-118%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Jazz Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Jazz Pharmaceuticals's revenue?: Jazz Pharmaceuticals (JAZZ) generated $4.4B in revenue over the trailing twelve months, up 9.2% year over year.
Is Jazz Pharmaceuticals profitable?: Jazz Pharmaceuticals is not currently profitable: it reported a net loss of $266.5M over the trailing twelve months, a -8.9% net margin.
What is Jazz Pharmaceuticals's earnings per share?: Jazz Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.75.
Where does Jazz Pharmaceuticals's income statement data come from?: Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.